|Intratumor heterogeneity and branched evolution revealed by multiregion sequencing|
M Gerlinger, AJ Rowan, S Horswell, J Larkin, D Endesfelder, E Gronroos, ...
N Engl j Med 366, 883-892, 2012
|Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing|
M Gerlinger, S Horswell, J Larkin, AJ Rowan, MP Salm, I Varela, R Fisher, ...
Nature genetics 46 (3), 225-233, 2014
|Spatial and temporal diversity in genomic instability processes defines lung cancer evolution|
EC de Bruin, N McGranahan, R Mitter, M Salm, DC Wedge, L Yates, ...
Science 346 (6206), 251-256, 2014
|Intratumor heterogeneity: seeing the wood for the trees|
TA Yap, M Gerlinger, PA Futreal, L Pusztai, C Swanton
Science translational medicine 4 (127), 127ps10-127ps10, 2012
|How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine|
M Gerlinger, C Swanton
British journal of cancer 103 (8), 1139-1143, 2010
|Classifying the evolutionary and ecological features of neoplasms|
CC Maley, A Aktipis, TA Graham, A Sottoriva, AM Boddy, M Janiszewska, ...
Nature Reviews Cancer 17 (10), 605-619, 2017
|Cancer evolution and the limits of predictability in precision cancer medicine|
KA Lipinski, LJ Barber, MN Davies, M Ashenden, A Sottoriva, M Gerlinger
Trends in cancer 2 (1), 49-63, 2016
|Cancer: evolution within a lifetime|
M Gerlinger, N McGranahan, SM Dewhurst, RA Burrell, I Tomlinson, ...
Annual review of genetics 48, 215-236, 2014
|SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair|
N Kanu, E Grönroos, P Martinez, RA Burrell, XY Goh, J Bartkova, ...
Oncogene 34 (46), 5699-5708, 2015
|Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers|
S Gulati, P Martinez, T Joshi, NJ Birkbak, CR Santos, AJ Rowan, ...
European urology 66 (5), 936-948, 2014
|Ultra‐deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas|
M Gerlinger, SA Quezada, KS Peggs, AJS Furness, R Fisher, T Marafioti, ...
The Journal of pathology 231 (4), 424-432, 2013
|Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications|
M Gerlinger, JW Catto, TF Orntoft, FX Real, EC Zwarthoff, C Swanton
European urology 67 (4), 729-737, 2015
|Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast …|
N Juul, Z Szallasi, AC Eklund, Q Li, RA Burrell, M Gerlinger, V Valero, ...
The lancet oncology 11 (4), 358-365, 2010
|Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loop|
J Kumbrink, M Gerlinger, JP Johnson
Journal of Biological Chemistry 280 (52), 42785-42793, 2005
|Genome‐wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target|
M Gerlinger, CR Santos, B Spencer‐Dene, P Martinez, D Endesfelder, ...
The Journal of pathology 227 (2), 146-156, 2012
|Parallel evolution of tumour subclones mimics diversity between tumours|
P Martinez, NJ Birkbak, M Gerlinger, N McGranahan, RA Burrell, ...
The Journal of pathology 230 (4), 356-364, 2013
|Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer|
A Woolston, K Khan, G Spain, LJ Barber, B Griffiths, R Gonzalez-Exposito, ...
Cancer cell 36 (1), 35-50. e9, 2019
|The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer|
K Sharpe, GD Stewart, A Mackay, C Van Neste, C Rofe, D Berney, ...
Clinical Cancer Research 19 (24), 6924-6934, 2013
|Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference|
DSW Tan, M Gerlinger, BT Teh, C Swanton
European Journal of Cancer 46 (12), 2166-2177, 2010
|Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution|
R Fisher, S Horswell, A Rowan, MP Salm, EC de Bruin, S Gulati, ...
Genome biology 15 (8), 1-15, 2014